Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice

American Journal of Chinese Medicine

Volumn 39, Issue 4, 2011, Pages 727-742

  Johnson, Thomas E ^a   Hermanson, David ^a   Wang, Lei ^b   Kassie, Fekadu ^b,c   Upadhyaya, Pramod ^c   O'Sullivan, Michael G ^b,c   Hecht, Stephen S ^c   Lu, Junxuan ^b,c   Xing, Chengguo ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

A J Mice; BaP; Chemoprevention; Flavokawains; Kava; Lung Tumorigenesis; NNK

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FLAVOKAWAINS A; FLAVOKAWAINS B; FLAVOKAWAINS C; KAVA EXTRACT; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; FOOD INTAKE; LIVER WEIGHT; LUNG ADENOMA; MOUSE; NONHUMAN;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZO(A)PYRENE; CARCINOGENS; CELL DEATH; CELL PROLIFERATION; CHALCONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; KAVA; LIVER; LUNG NEOPLASMS; MICE; MICE, INBRED STRAINS; NITROSAMINES; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 79959950118     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0192415X11009202     Document Type: Article

References (47)

1. Anke, J. and I. Ramzan. Kava hepatotoxicity: are we any closer to the truth? Planta Med. 70: 193-196, 2004. (Pubitemid 38445182)
2. Baba, M., R. Asano, I. Takigami, T. Takahashi, M. Ohmura, Y. Okada, H. Sugimoto, T. Arika, H. Nishino and T. Okuyama. Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol. Pharm. Bull. 25: 247-250, 2002. (Pubitemid 39592115)
3. Boeck, P., C.A. Bandeira Falcao, P.C. Leal, R.A. Yunes, V.C. Filho, E.C. Torres-Santos and B. Rossi-Bergmann. Synthesis of chalcone analogues with increased antileishmanial activity. Bioorg. Med. Chem. 14: 1538-1545, 2006. (Pubitemid 43120289)
4. Clayton, N.P., K. Yoshizawa, G.E. Kissling, L.T. Burka, P.C. Chan and A. Nyska. Immunohisto-chemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp. Toxicol. Pathol. 58: 223-236, 2007. (Pubitemid 44873076)
5. Clouatre, D.L. Kava kava: examining new reports of toxicity. Toxicol. Lett. 150: 85-96, 2004. (Pubitemid 38447238)
6. Conaway, C.C., C.X. Wang, B. Pittman, Y.M. Yang, J.E. Schwartz, D. Tian, E.J. McIntee, S.S. Hecht and F.L. Chung. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. Cancer Res. 65: 8548-8557, 2005. (Pubitemid 41330624)
7. Cosci, F., A. Corlando, E. Fornai, F. Pistelli, P. Paoletti and L. Carronni. Nicotine dependence, psychological distress and personality traits as possible predictors of smoking cessation. Results of a double-blind study with nicotin patch. Addict Behav. 34: 28-35, 2009.
8. Côté, C.S., C. Kor, J. Cohen and K. Auclair. Composition and biological activity of traditional and commercial kava extracts. Biochem. Biophys. Res. Commun. 322: 147-152, 2004. (Pubitemid 39093851)
9. Cuendet, M., C.P. Oteham, R.C. Moon and J.M. Pezzuto. Quinone reductase induction as a bio-marker for cancer chemoprevention. J. Nat. Prod. 69: 460-463, 2006.
10. Denham, A., M. McIntyre and J. Whitehouse. Kava - the unfolding story: report on a work-in-progress. J. Altern. Complement. Med. 8: 237-263, 2002. (Pubitemid 34753400)
11. Enstrom, J.E. and C.W. Heath Jr. Smoking cessation and mortality trends among 118,000 Cali-fornians, 1960-1997. Epidemiology 10: 500-512, 1999.
12. Ernst, E. A re-evaluation of kava (Piper methysticum). Br. J. Clin. Pharmacol. 64: 415-417, 2007. (Pubitemid 47404312)
13. Folmer, F., R. Blasius, F. Morceau, J. Tabudravu, M. Dicato, M. Jaspars and M. Diederich. Inhibition of TNFalpha-induced activation of nuclear factor kappaB by kava (Piper methysticum) derivatives. Biochem. Pharmacol. 71: 1206-1218, 2006. (Pubitemid 43357901)
14. Hashimoto, T., M. Suganuma, H. Fujiki, M. Yamada, T. Kohno and Y. Asakawa. Isolation and synthesis of TNF-alpha release inhibitors from Fijian kawa (Piper methysticum). Phytomedi-cine 10: 309-317, 2003. (Pubitemid 36597167)
15. Hecht, S.S., S. Isaacs and N. Trushin. Lung tumor induction in A/J mice by the tobacco smoke carcinogens 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone and benzo[a]pyrene: a potentially useful model for evaluation of chemopreventive agents. Carcinogenesis 15: 2721-2725, 1994.
16. Hecht, S.S., D. Lin and A. Castonguay. Effects of alpha-deuterium substitution on the mutagenicity of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1- butanone (NNK). Carcinogenesis 4: 305-310, 1983. (Pubitemid 13091947)
17. Henderson, B.E., L.N. Kolonel, R. Dworsky, D. Kerford, E. Mori, K. Singh and H. Theveno. Cancer incidence in the islands of the pacific. In: Fourth Symposium on Epidemiology and Cancer Registries in the Pacific Basin, Kona, Hawaii, 1984, pp. 73-81. (Pubitemid 16158039)
18. Hughes, J.R., J. Keely and S. Naud. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 99: 29-38, 2004. (Pubitemid 38142221)
19. Imai, K., K. Suga and K. Nakachi. Cancer-preventive effects of drinking green tea among a Japanese population. Prev. Med. 26: 769-775, 1997. (Pubitemid 27508650)
20. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5: 6-13, 2005. (Pubitemid 40220611)
21. Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu and M.J. Thun. Cancer statistics, 2009. CA Cancer J. Clin. 59: 225-249, 2009.
22. Johnson, B.M., S.X. Qiu, S. Zhang, F. Zhang, J.E. Burdette, L. Yu, J.L. Bolton and R.B. Van Breemen. Identification of novel electrophilic metabolites of piper methysticum Forst (kava). Chem. Res. Toxicol. 16: 733-740, 2003. (Pubitemid 36736604)
23. Johnson, T.E., F. Kassie, M.G. O'Sullivan, M. Negia, T.E. Hanson, P. Upadhyaya, P.P. Ruvolo, S.S. Hecht and C. Xing. Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumorigenesis in A/J Mice. Cancer Prev. Res. 1: 430-438, 2008.
24. Kassie, F., L.B. Anderson, R. Scherber, N. Yu, D. Lahti, P. Upadhyaya and S.S. Hecht. Indole-3-carbinol inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone plus benzo(a)pyrene-induced lung tumorigenesis in A/J mice and modulates carcinogen-induced alterations in protein levels. Cancer Res. 67: 6502-6511, 2007. (Pubitemid 47037536)
25. Kim, Y.H., J. Kim, H. Park and H.P. Kim. Anti-inflammatory activity of the synthetic chalcone derivatives: inhibition of inducible nitric oxide synthase-catalyzed nitric oxide production from lipopolysaccharide-treated RAW 264.7 cells. Biol. Pharm. Bull. 30: 1450-1455, 2007. (Pubitemid 47282192)
26. Kumar, S., A. Sharma, B. Madan, V. Singhal and B. Ghosh. Isoliquiritigenin inhibits IkappaB kinase activity and ROS generation to block TNF-alpha induced expression of cell adhesion molecules on human endothelial cells. Biochem. Pharmacol. 73: 1602-1612, 2007. (Pubitemid 46533973)
27. Makita, H., T. Tanaka, H. Fujitsuka, N. Tatematsu, K. Satoh, A. Hara and H. Mori. Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercetin. Cancer Res. 56: 4904-4909, 1996. (Pubitemid 26374427)
28. Meissner, O. and H. Häberlein. HPLC analysis of flavokavins and kavapyrones from Piper methysticum Forst. J. Chromatogr. B826: 46-49, 2005. (Pubitemid 41446433)
29. Nerurkar, P. V., K. Dragull and C. S. Tang. In vitro toxicity of kava alkaloid, Piper methystine, in HepG2 cells compared to kavalactones. Toxicol. Sci. 79: 106-111, 2004. (Pubitemid 38660254)
30. Pandey, M. K, S. K. Sandur, B. Sung, G Sethi, A.B. Kunnumakkara and B.B. Aggarwal. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J. Biol. Chem. 282: 17340-17350, 2007. (Pubitemid 47100316)
31. Peto, R., S. Darby, H. Deo, P. Silcocks, E. Whitley and R. Doll. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Br. Med. J. 321: 323-329, 2000.
32. Poolsup, N., W. Li, A. Po and T.L. Knight. Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther. 25: 197-220, 2000.
33. Sale, S., R.G Tunstall, K.C. Ruparelia, P.C. Butler, GA. Potter, W.P. Steward and A.J. Gescher. Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin + mouse. Invest. New Drugs 24: 459-464, 2006. (Pubitemid 44273020)
34. Schulze, J., W. Raasch and C.P. Siegers. Toxicity of kava pyrones, drug safety and precautions - a case study. Phytomedicine 10: 68-73, 2003. (Pubitemid 36597161)
35. Stead, L.F., R. Perera, C. Bullen, D. Mant and T. Lancaster. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 1: CD000146, 2008.
36. Steiner, G.G The correlation between cancer incidence and kava consumption. Hawaii Med. J., 59, 420-422, 2000
37. Stickel, F., H.M. Baumuller, K. Seitz, D. Vasilakis, G. Seitz, H.K. Seitz and D. Schuppan. Hepatitis induced by Kava (Piper methysticum rhizoma). J. Hepatol. 39: 62-67, 2003. (Pubitemid 36724109)
38. Takahashi, T., N. Takasuka, M. Iigo, M. Baba, H. Nishino, H. Tsuda and T. Okuyama. Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development. Cancer Sci. 95: 448-453, 2004. (Pubitemid 38832690)
39. Tang, Y., A. R. Simoneau, J. Xie, B. Shahandeh and X. Zi. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prev. Res. 1: 439-451, 2008.
40. Teschke, R., A. Schwarzenboeck and K.H. Hennermann. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur. J. Gastroenterol. Hepatol. 20: 1182-1193, 2008.
41. Tuomilehto, J., P. Zimmet, R. Taylor, P. Bennet, E. Wolf and J. Kankaanpaa. Smoking rates in Pacific islands. Bull. World Health Organ. 64: 447-456, 1986. (Pubitemid 16020991)
42. Wanwimolruk, S., S. Bhawan, P.F. Coville and S.C. Chalcroft. Genetic polymorphism of debriso-quine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Eur. J. Clin. Pharmacol. 54: 431-435, 1998. (Pubitemid 28396318)
43. Wattenberg, L.W. Chalcones, myo-inositol and other novel inhibitors of pulmonary carcinogenesis. J. Cell Biochem. Suppl. 22: 162-168, 1995.
44. Wattenberg, L.W., J.B. Coccia and A.R. Galbraith. Inhibition of carcinogen-induced pulmonary and mammary carcinogenesis by chalcone administered subsequent to carcinogen exposure. Cancer Lett. 83: 165-169, 1994. (Pubitemid 24253533)
45. Xuan, T.D., M. Fukuta, A.C. Wei, A.A. Elzaawely, T.D. Khanh and S. Tawata. Efficacy of extracting solvents to chemical components of kava (Piper methysticum) roots. Nat. Med. 62: 188-194, 2008. (Pubitemid 351365814)
46. Yamazaki, Y., H. Hashida, A. Arita, K Hamaguchi and F. Shimura. High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food Chem. Toxicol. 46: 3732-3738, 2008.
47. Zi, X. and A.R. Simoneau. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res. 65: 3479-3486, 2005. (Pubitemid 40524635)